CancerVax Ends Development of Melanoma Vaccine Canvaxin
CancerVax is dropping development of its cancer vaccine Canvaxin after a data safety monitoring board concludes a Phase III trial in stage III melanoma will not show a survival benefit.
CancerVax is dropping development of its cancer vaccine Canvaxin after a data safety monitoring board concludes a Phase III trial in stage III melanoma will not show a survival benefit.